334 related articles for article (PubMed ID: 32669442)
1. Structure-based development of a subtype-selective orexin 1 receptor antagonist.
Hellmann J; Drabek M; Yin J; Gunera J; Pröll T; Kraus F; Langmead CJ; Hübner H; Weikert D; Kolb P; Rosenbaum DM; Gmeiner P
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18059-18067. PubMed ID: 32669442
[TBL] [Abstract][Full Text] [Related]
2. Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA.
Suno R; Kimura KT; Nakane T; Yamashita K; Wang J; Fujiwara T; Yamanaka Y; Im D; Horita S; Tsujimoto H; Tawaramoto MS; Hirokawa T; Nango E; Tono K; Kameshima T; Hatsui T; Joti Y; Yabashi M; Shimamoto K; Yamamoto M; Rosenbaum DM; Iwata S; Shimamura T; Kobayashi T
Structure; 2018 Jan; 26(1):7-19.e5. PubMed ID: 29225076
[TBL] [Abstract][Full Text] [Related]
3. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.
Yin J; Babaoglu K; Brautigam CA; Clark L; Shao Z; Scheuermann TH; Harrell CM; Gotter AL; Roecker AJ; Winrow CJ; Renger JJ; Coleman PJ; Rosenbaum DM
Nat Struct Mol Biol; 2016 Apr; 23(4):293-9. PubMed ID: 26950369
[TBL] [Abstract][Full Text] [Related]
4. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.
Yin J; Mobarec JC; Kolb P; Rosenbaum DM
Nature; 2015 Mar; 519(7542):247-50. PubMed ID: 25533960
[TBL] [Abstract][Full Text] [Related]
6. Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation.
Vitale RM; Iannotti FA; Schiano Moriello A; Tunisi L; Piscitelli F; Savopoulos R; Cristino L; De Petrocellis L; Amodeo P; Gray R; Di Marzo V
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439801
[TBL] [Abstract][Full Text] [Related]
7. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
[TBL] [Abstract][Full Text] [Related]
8. Investigation of New Orexin 2 Receptor Modulators Using
Janockova J; Dolezal R; Nepovimova E; Kobrlova T; Benkova M; Kuca K; Konecny J; Mezeiova E; Melikova M; Hepnarova V; Ring A; Soukup O; Korabecny J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423961
[TBL] [Abstract][Full Text] [Related]
9. Interaction modes of human orexin 2 receptor with selective and nonselective antagonists studied by NMR spectroscopy.
Imamura K; Akagi KI; Miyanoiri Y; Tsujimoto H; Hirokawa T; Ashida H; Murakami K; Inoue A; Suno R; Ikegami T; Sekiyama N; Iwata S; Kobayashi T; Tochio H
Structure; 2024 Mar; 32(3):352-361.e5. PubMed ID: 38194963
[TBL] [Abstract][Full Text] [Related]
10. Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists.
Skudlarek JW; DiMarco CN; Babaoglu K; Roecker AJ; Bruno JG; Pausch MA; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Wuelfing WP; Garson SL; Fox SV; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Kuduk SD; Coleman PJ
Bioorg Med Chem Lett; 2017 Mar; 27(6):1364-1370. PubMed ID: 28216403
[TBL] [Abstract][Full Text] [Related]
11. Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity.
Saitoh T; Seki K; Nakajima R; Yamamoto N; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2019 Sep; 29(18):2655-2658. PubMed ID: 31375290
[TBL] [Abstract][Full Text] [Related]
12. Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor.
Yamamoto N; Ohrui S; Okada T; Yata M; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4176-4179. PubMed ID: 28739044
[TBL] [Abstract][Full Text] [Related]
13. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Discovery of Novel Ligands for the Orexin 2 Receptor.
Gunera J; Baker JG; van Hilten N; Rosenbaum DM; Kolb P
J Med Chem; 2020 Oct; 63(19):11045-11053. PubMed ID: 32977721
[TBL] [Abstract][Full Text] [Related]
15. Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring.
Yamamoto N; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
Bioorg Med Chem; 2019 Apr; 27(8):1747-1758. PubMed ID: 30871861
[TBL] [Abstract][Full Text] [Related]
16. Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A.
Messal N; Fernandez N; Dayot S; Gratio V; Nicole P; Prochasson C; Chantret I; LeGuilloux G; Jarry A; Couvelard A; Tréton X; Voisin T; Ogier-Denis E; Couvineau A
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3618-3628. PubMed ID: 30251681
[TBL] [Abstract][Full Text] [Related]
17. Design and Synthesis of Orexin 1 Receptor-Selective Agonists.
Iio K; Hashimoto K; Nagumo Y; Amezawa M; Hasegawa T; Yamamoto N; Kutsumura N; Takeuchi K; Ishikawa Y; Yamamoto H; Tokuda A; Sato T; Uchida Y; Inoue A; Tanimura R; Yanagisawa M; Nagase H; Saitoh T
J Med Chem; 2023 Apr; 66(8):5453-5464. PubMed ID: 37043436
[TBL] [Abstract][Full Text] [Related]
18. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation.
Hong C; Byrne NJ; Zamlynny B; Tummala S; Xiao L; Shipman JM; Partridge AT; Minnick C; Breslin MJ; Rudd MT; Stachel SJ; Rada VL; Kern JC; Armacost KA; Hollingsworth SA; O'Brien JA; Hall DL; McDonald TP; Strickland C; Brooun A; Soisson SM; Hollenstein K
Nat Commun; 2021 Feb; 12(1):815. PubMed ID: 33547286
[TBL] [Abstract][Full Text] [Related]
19. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.
Dugovic C; Shelton JE; Aluisio LE; Fraser IC; Jiang X; Sutton SW; Bonaventure P; Yun S; Li X; Lord B; Dvorak CA; Carruthers NI; Lovenberg TW
J Pharmacol Exp Ther; 2009 Jul; 330(1):142-51. PubMed ID: 19363060
[TBL] [Abstract][Full Text] [Related]
20. Dynein light chain Tctex-type 1 modulates orexin signaling through its interaction with orexin 1 receptor.
Duguay D; Bélanger-Nelson E; Mongrain V; Beben A; Khatchadourian A; Cermakian N
PLoS One; 2011; 6(10):e26430. PubMed ID: 22028875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
